Ottavia Cozzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ottavia Cozzi has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Damiano Regazzoli
IRCCS Humanitas Research Hospital , Via Manzoni 56, 20089 Rozzano, Milan
4 shared publicationsAntonio Mangieri
IRCCS Humanitas Research Hospital , Via Manzoni 56, 20089 Rozzano, Milan
3 shared publications- Giulio Giuseppe Stefanini
Department of Biomedical Sciences, Humanitas University, Milan, Italy
3 shared publications Bernhard Reimers
IRCCS Humanitas Research Hospital , Via Manzoni 56, 20089 Rozzano, Milan
2 shared publications- Gabriele Luigi Gasparini
Cardio Center IRCCS Humanitas Research Hospital Rozzano‐Milan Italy
2 shared publications Gianluigi Condorelli
Department of Biomedical Sciences, Humanitas University , Via Rita Levi Montalcini 4, Pieve Emanuele, Milan 20072
2 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (8) , e70245
Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management
Background: Calcific aortic stenosis (AS) is the most relevant valvular heart disease in aging populations and remains both underdiagnosed and undertreated. Screening studies reveal a high prevalence of unrecognized disease, while up to 40% of patients with symptomatic severe AS do not undergo valve intervention, resulting in poor survival. No pharmacologic therapy has yet altered disease progression, although targeted approaches such as lipoprotein(a) inhibition are under investigation. Methods: This paper provides a comprehensive perspective review of the evolving epidemiology, timing of intervention, and long‐term management of aortic stenosis, drawing on randomized trials and contemporary clinical data. Results: Randomized trials have challenged the traditional watchful waiting strategy in asymptomatic severe AS, showing that early aortic valve replacement (AVR) reduces cardiovascular events, though survival benefit depends on patient selection and timing. Moderate AS is increasingly recognized as a high‐risk condition, prompting ongoing trials evaluating earlier intervention. As transcatheter aortic valve implantation (TAVI) expands to younger, lower‐risk patients, long‐term issues—including conduction disturbances, paravalvular leak, cerebrovascular events, valve hemodynamics and durability, and redo feasibility—become central to care. Contemporary data suggest comparable mid‐term durability between TAVI and surgery, but lifetime management planning is essential. Conclusions: Optimal care of aortic stenosis requires earlier diagnosis, optimized procedural strategies, and a lifetime‐oriented approach to management, supported by continued investigation into pharmacologic therapy and the timing of intervention.
- 13 August 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (8) , e70245
Open AccessContemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management
Background: Calcific aortic stenosis (AS) is the most relevant valvular heart disease in aging populations and remains both underdiagnosed and undertreated. Screening studies reveal a high prevalence of unrecognized disease, while up to 40% of patients with symptomatic severe AS do not undergo valve intervention, resulting in poor survival. No pharmacologic therapy has yet altered disease progression, although targeted approaches such as lipoprotein(a) inhibition are under investigation. Methods: This paper provides a comprehensive perspective review of the evolving epidemiology, timing of intervention, and long‐term management of aortic stenosis, drawing on randomized trials and contemporary clinical data. Results: Randomized trials have challenged the traditional watchful waiting strategy in asymptomatic severe AS, showing that early aortic valve replacement (AVR) reduces cardiovascular events, though survival benefit depends on patient selection and timing. Moderate AS is increasingly recognized as a high‐risk condition, prompting ongoing trials evaluating earlier intervention. As transcatheter aortic valve implantation (TAVI) expands to younger, lower‐risk patients, long‐term issues—including conduction disturbances, paravalvular leak, cerebrovascular events, valve hemodynamics and durability, and redo feasibility—become central to care. Contemporary data suggest comparable mid‐term durability between TAVI and surgery, but lifetime management planning is essential. Conclusions: Optimal care of aortic stenosis requires earlier diagnosis, optimized procedural strategies, and a lifetime‐oriented approach to management, supported by continued investigation into pharmacologic therapy and the timing of intervention.
- Open Access
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (5) , oeaf095
Clinical outcomes of percutaneous coronary interventions after transcatheter aortic valve replacement
Aims: The number of patients undergoing percutaneous coronary interventions (PCI) after transcatheter aortic valve replacement (TAVR) is expected to increase, but their prognosis remains poorly understood. Methods and results: Consecutive PCI patients with prior TAVR were compared to patients without prior TAVR between 2008 and 2023. The Kaplan–Meier method was used to estimate the 1-year incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death or myocardial infarction. An entropy balance approach was implemented to adjust for imbalances in patient and procedural characteristics. Adjusted hazard ratios (HRs) were estimated using weighted Cox regression models. Comparing 420 PCI patients with prior TAVR (mean age 80.8 years, 37.1% women) to 1197 without (mean age 70.4 years, 24.6% women), 1-year MACE was higher in the prior TAVR group (8.7 vs. 3.7%; unadjusted HR 2.35, 95% CI 1.49–3.69; P < 0.001). After adjustment for clinical and procedural characteristics, prior TAVR remained associated with an increased risk of MACE (adjusted HR 2.36, 95% CI 1.08–5.16; P = 0.032). This was primarily driven by higher cardiovascular death (adjusted HR 3.12, 95% CI 1.10–8.79, P = 0.032), while the association with myocardial infarction was attenuated post-adjustment and no longer statistically significant. Conclusion: Patients undergoing PCI after TAVR experience a higher incidence of MACE compared to those undergoing PCI without prior TAVR, underscoring the importance of accurate patient selection before performing PCI in patients with chronic coronary syndrome and history of TAVR.
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 5 (5) , oeaf095
Open AccessClinical outcomes of percutaneous coronary interventions after transcatheter aortic valve replacement
Aims: The number of patients undergoing percutaneous coronary interventions (PCI) after transcatheter aortic valve replacement (TAVR) is expected to increase, but their prognosis remains poorly understood. Methods and results: Consecutive PCI patients with prior TAVR were compared to patients without prior TAVR between 2008 and 2023. The Kaplan–Meier method was used to estimate the 1-year incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death or myocardial infarction. An entropy balance approach was implemented to adjust for imbalances in patient and procedural characteristics. Adjusted hazard ratios (HRs) were estimated using weighted Cox regression models. Comparing 420 PCI patients with prior TAVR (mean age 80.8 years, 37.1% women) to 1197 without (mean age 70.4 years, 24.6% women), 1-year MACE was higher in the prior TAVR group (8.7 vs. 3.7%; unadjusted HR 2.35, 95% CI 1.49–3.69; P < 0.001). After adjustment for clinical and procedural characteristics, prior TAVR remained associated with an increased risk of MACE (adjusted HR 2.36, 95% CI 1.08–5.16; P = 0.032). This was primarily driven by higher cardiovascular death (adjusted HR 3.12, 95% CI 1.10–8.79, P = 0.032), while the association with myocardial infarction was attenuated post-adjustment and no longer statistically significant. Conclusion: Patients undergoing PCI after TAVR experience a higher incidence of MACE compared to those undergoing PCI without prior TAVR, underscoring the importance of accurate patient selection before performing PCI in patients with chronic coronary syndrome and history of TAVR.
- Open Access
- 13 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (1) , qyaf018
The impact of bicuspid valve morphology on the selection of transcatheter aortic valve implantation devices: an in silico study
Aims: Bicuspid aortic valve (BAV) represents a challenge for transcatheter aortic valve implantation (TAVI). Few data are reported about the procedural implications of BAV using different self-expandable devices. The aim of this study is to investigate how BAV and tricuspid aortic valve (TAV) morphologies influence device selection and their impact on the potential development of post-operative conduction disturbances, using a novel in silico approach. Methods and results: Five patients with BAV undergoing TAVI were enrolled. TAVs were virtually modelled within each BAV patient-specific anatomy, resulting in 10 virtual patients. Acurate Neo2 and Evolut R implantations were subsequently simulated across all cases. Post-implantation stresses exerted on both the stent and aortic root were measured, allowing a comparative analysis of the impact of the two valve morphologies. Comparing stent stresses between BAV and TAV configurations, the stress gap increased by 21.96 ± 5.35% (P = 0.01) in Acurate Neo2 cases (n = 6) compared with Evolut R cases (n = 4). The analysis of aortic root stresses showed no significant differences between BAV (n = 5) and TAV (n = 5) configurations, with a mean stress difference of 5.1 ± 8.17% (P > 0.05). Conclusion: Our patient-specific model shows that high radial force devices, such as Evolut R, demonstrate consistent expansion regardless of valve morphology, without increasing the risk of post-implantation conduction disturbances, hence resulting more suitable for BAV cases. Incorporating this methodology into pre-operative planning could support clinicians in selecting the most suitable device with a patient-specific approach.
- 13 January 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 3 (1) , qyaf018
Open AccessThe impact of bicuspid valve morphology on the selection of transcatheter aortic valve implantation devices: an in silico study
Aims: Bicuspid aortic valve (BAV) represents a challenge for transcatheter aortic valve implantation (TAVI). Few data are reported about the procedural implications of BAV using different self-expandable devices. The aim of this study is to investigate how BAV and tricuspid aortic valve (TAV) morphologies influence device selection and their impact on the potential development of post-operative conduction disturbances, using a novel in silico approach. Methods and results: Five patients with BAV undergoing TAVI were enrolled. TAVs were virtually modelled within each BAV patient-specific anatomy, resulting in 10 virtual patients. Acurate Neo2 and Evolut R implantations were subsequently simulated across all cases. Post-implantation stresses exerted on both the stent and aortic root were measured, allowing a comparative analysis of the impact of the two valve morphologies. Comparing stent stresses between BAV and TAV configurations, the stress gap increased by 21.96 ± 5.35% (P = 0.01) in Acurate Neo2 cases (n = 6) compared with Evolut R cases (n = 4). The analysis of aortic root stresses showed no significant differences between BAV (n = 5) and TAV (n = 5) configurations, with a mean stress difference of 5.1 ± 8.17% (P > 0.05). Conclusion: Our patient-specific model shows that high radial force devices, such as Evolut R, demonstrate consistent expansion regardless of valve morphology, without increasing the risk of post-implantation conduction disturbances, hence resulting more suitable for BAV cases. Incorporating this methodology into pre-operative planning could support clinicians in selecting the most suitable device with a patient-specific approach.
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12) , e013232
Drug-Coated Balloon Angioplasty for De Novo Lesions on the Left Anterior Descending Artery
BACKGROUND: Drug-coated balloons (DCB) are an emerging tool for modern percutaneous coronary intervention (PCI), but evidence on their use for de novo lesions on large vessels is limited. METHODS: Consecutive patients undergoing DCB-based PCI on the left anterior descending artery in 2 Italian centers from 2018 to 2022 were retrospectively enrolled and compared with patients who received left anterior descending PCI with contemporary drug-eluting stents (DES). In-stent restenosis was excluded. The DCB group included both patients undergoing DCB-only PCI and those receiving hybrid PCI with DCB and DES combined. The primary end point was target lesion failure at 2 years, defined as the composite of target lesion revascularization, cardiac death, and target vessel myocardial infarction. RESULTS: We included 147 consecutive patients undergoing DCB-based treatment on the left anterior descending artery and compared them to 701 patients who received conventional PCI with DES. In the DCB group, 43 patients (29.2%) were treated with DCB only and 104 (70.8%) with a hybrid approach; DCB length was greater than stent length in 55.1% of cases. Total treated length was higher in the DCB group (65 [40–82] versus 56 [46–66] mm; P =0.002), while longer DESs were implanted (38 [24–62] versus 56 [46–66] mm; P P =0.036) in the DES cohort. The cumulative 2-year target lesion failure incidence was not significantly different between the 2 groups (DCB, 4.1% versus DES, 9.8%; hazard ratio, 0.51 [95% CI, 0.20–1.27]; P =0.15). After a 1:1 propensity score matching resulting in 139 matched pairs, the DCB-based treatment was associated with a lower risk for target lesion failure at 2 years compared with DES-only PCI (hazard ratio, 0.2 [95% CI, 0.07–0.58]; P =0.003), mainly driven by less target lesion revascularization. CONCLUSIONS: A DCB-based treatment approach for left anterior descending revascularization allows a significantly reduced stent burden, thereby potentially limiting target lesion failure risk at midterm follow-up.
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12) , e013232
Drug-Coated Balloon Angioplasty for De Novo Lesions on the Left Anterior Descending Artery
BACKGROUND: Drug-coated balloons (DCB) are an emerging tool for modern percutaneous coronary intervention (PCI), but evidence on their use for de novo lesions on large vessels is limited. METHODS: Consecutive patients undergoing DCB-based PCI on the left anterior descending artery in 2 Italian centers from 2018 to 2022 were retrospectively enrolled and compared with patients who received left anterior descending PCI with contemporary drug-eluting stents (DES). In-stent restenosis was excluded. The DCB group included both patients undergoing DCB-only PCI and those receiving hybrid PCI with DCB and DES combined. The primary end point was target lesion failure at 2 years, defined as the composite of target lesion revascularization, cardiac death, and target vessel myocardial infarction. RESULTS: We included 147 consecutive patients undergoing DCB-based treatment on the left anterior descending artery and compared them to 701 patients who received conventional PCI with DES. In the DCB group, 43 patients (29.2%) were treated with DCB only and 104 (70.8%) with a hybrid approach; DCB length was greater than stent length in 55.1% of cases. Total treated length was higher in the DCB group (65 [40–82] versus 56 [46–66] mm; P =0.002), while longer DESs were implanted (38 [24–62] versus 56 [46–66] mm; P P =0.036) in the DES cohort. The cumulative 2-year target lesion failure incidence was not significantly different between the 2 groups (DCB, 4.1% versus DES, 9.8%; hazard ratio, 0.51 [95% CI, 0.20–1.27]; P =0.15). After a 1:1 propensity score matching resulting in 139 matched pairs, the DCB-based treatment was associated with a lower risk for target lesion failure at 2 years compared with DES-only PCI (hazard ratio, 0.2 [95% CI, 0.07–0.58]; P =0.003), mainly driven by less target lesion revascularization. CONCLUSIONS: A DCB-based treatment approach for left anterior descending revascularization allows a significantly reduced stent burden, thereby potentially limiting target lesion failure risk at midterm follow-up.
- Open Access
- 7 November 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (6) , 1048-1056
Clinical and procedural outcomes of percutaneous coronary intervention for de novo lesions involving the ostial left circumflex coronary artery
Background: Percutaneous treatment for ostial left circumflex artery (LCx) lesions is known to be associated with suboptimal results.Aims: The present study aims to assess the procedural and long‐term clinical outcomes of percutaneous coronary intervention (PCI) for de novo ostial LCx lesions overall and according to the coronary revascularization strategy.Methods: Consecutive patients undergoing PCI with second generation drug eluting stents or drug coated balloons for de novo ostial LCx lesions in three high‐volume Italian centers between 2012 and 2021 were retrospectively evaluated. The primary endpoint was target‐vessel revascularization (TVR) at 2 years. Secondary endpoints included major adverse cardiovascular and cerebrovascular events (MACCE), target lesion revascularization, myocardial infarction, stroke, all‐cause death, and repeat revascularization.Results: A total of 366 patients were included in the analysis with a median follow‐up of 901 (IQR: 450−1728) days. 79.5% of the patients were male, 33.6% were diabetic, 49.7% had a previous PCI, and 23.1% a prior surgical revascularization. Very ostial LCx stenting was performed in 34.1%, crossover from left main to LCx in 17.3%, and a two‐stent strategy in 48.6% of cases, respectively. In the overall population, the incidence of TVR at 2 years was 19.0% while MACCE rate was 25.7%. No major differences in clinical outcomes were found according to the stenting strategy. Use of intracoronary imaging was associated with fewer MACCE (HR: 0.47, 95% CI: 0.25−1.13, p = 0.01), while the diameter of the stent implanted in the ostial LCx was associated with less TVR (HR: 0.43, 95% CI: 0.25−0.75, p = 0.002).Conclusions: Percutaneous revascularization of the ostial LCx is associated with a high rate of TVR, regardless of the stenting strategy. Intracoronary imaging and proper stent sizing may reduce the failure rates.
- 7 November 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (6) , 1048-1056
Open AccessClinical and procedural outcomes of percutaneous coronary intervention for de novo lesions involving the ostial left circumflex coronary artery
Background: Percutaneous treatment for ostial left circumflex artery (LCx) lesions is known to be associated with suboptimal results.Aims: The present study aims to assess the procedural and long‐term clinical outcomes of percutaneous coronary intervention (PCI) for de novo ostial LCx lesions overall and according to the coronary revascularization strategy.Methods: Consecutive patients undergoing PCI with second generation drug eluting stents or drug coated balloons for de novo ostial LCx lesions in three high‐volume Italian centers between 2012 and 2021 were retrospectively evaluated. The primary endpoint was target‐vessel revascularization (TVR) at 2 years. Secondary endpoints included major adverse cardiovascular and cerebrovascular events (MACCE), target lesion revascularization, myocardial infarction, stroke, all‐cause death, and repeat revascularization.Results: A total of 366 patients were included in the analysis with a median follow‐up of 901 (IQR: 450−1728) days. 79.5% of the patients were male, 33.6% were diabetic, 49.7% had a previous PCI, and 23.1% a prior surgical revascularization. Very ostial LCx stenting was performed in 34.1%, crossover from left main to LCx in 17.3%, and a two‐stent strategy in 48.6% of cases, respectively. In the overall population, the incidence of TVR at 2 years was 19.0% while MACCE rate was 25.7%. No major differences in clinical outcomes were found according to the stenting strategy. Use of intracoronary imaging was associated with fewer MACCE (HR: 0.47, 95% CI: 0.25−1.13, p = 0.01), while the diameter of the stent implanted in the ostial LCx was associated with less TVR (HR: 0.43, 95% CI: 0.25−0.75, p = 0.002).Conclusions: Percutaneous revascularization of the ostial LCx is associated with a high rate of TVR, regardless of the stenting strategy. Intracoronary imaging and proper stent sizing may reduce the failure rates.
- Open Access
- 4 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (13) , e029735
Acute Reduction in Left Ventricular Function Following Transcatheter Mitral Edge‐to‐Edge Repair
Background: Little is known about the impact of transcatheter mitral valve edge‐to‐edge repair on changes in left ventricular ejection fraction (LVEF) and the effect of an acute reduction in LVEF on prognosis. We aimed to assess changes in LVEF after transcatheter mitral valve edge‐to‐edge repair for both primary and secondary mitral regurgitation (PMR and SMR, respectively), identify rates and predictors of LVEF reduction, and estimate its impact on prognosis. Methods and Results: In this international multicenter registry, patients with both PMR and SMR undergoing transcatheter mitral valve edge‐to‐edge repair were included. We assessed rates of acute LVEF reduction (LVEFR), defined as an acute relative decrease of >15% in LVEF, its impact on all‐cause mortality, major adverse cardiac event (composite end point of all‐cause death, mitral valve surgery, and residual mitral regurgitation grade ≥2), and LVEF at 12 months, as well as predictors for LVEFR. Of 2534 patients included (727 with PMR, and 1807 with SMR), 469 (18.5%) developed LVEFR. Patients with PMR were older (79.0±9.2 versus 71.8±8.9 years; P P P P P =0.236). LVEF at baseline (odds ratio, 1.03 [95% CI, 1.01–1.05]; P =0.002) was predictive of LVEFR for patients with PMR, but not those with SMR ( P =0.092). Conclusions: Reduction in LVEF is not uncommon after transcatheter mitral valve edge‐to‐edge repair and is correlated with worsened prognosis in patients with PMR but not patients with SMR. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05311163.
- 4 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (13) , e029735
Open AccessAcute Reduction in Left Ventricular Function Following Transcatheter Mitral Edge‐to‐Edge Repair
Background: Little is known about the impact of transcatheter mitral valve edge‐to‐edge repair on changes in left ventricular ejection fraction (LVEF) and the effect of an acute reduction in LVEF on prognosis. We aimed to assess changes in LVEF after transcatheter mitral valve edge‐to‐edge repair for both primary and secondary mitral regurgitation (PMR and SMR, respectively), identify rates and predictors of LVEF reduction, and estimate its impact on prognosis. Methods and Results: In this international multicenter registry, patients with both PMR and SMR undergoing transcatheter mitral valve edge‐to‐edge repair were included. We assessed rates of acute LVEF reduction (LVEFR), defined as an acute relative decrease of >15% in LVEF, its impact on all‐cause mortality, major adverse cardiac event (composite end point of all‐cause death, mitral valve surgery, and residual mitral regurgitation grade ≥2), and LVEF at 12 months, as well as predictors for LVEFR. Of 2534 patients included (727 with PMR, and 1807 with SMR), 469 (18.5%) developed LVEFR. Patients with PMR were older (79.0±9.2 versus 71.8±8.9 years; P P P P P =0.236). LVEF at baseline (odds ratio, 1.03 [95% CI, 1.01–1.05]; P =0.002) was predictive of LVEFR for patients with PMR, but not those with SMR ( P =0.092). Conclusions: Reduction in LVEF is not uncommon after transcatheter mitral valve edge‐to‐edge repair and is correlated with worsened prognosis in patients with PMR but not patients with SMR. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05311163.
- Open Access
- 31 January 2022
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 1 (1)
We Now Have a Tool to Optimally Implant Stents
- 31 January 2022
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 1 (1)
Open AccessWe Now Have a Tool to Optimally Implant Stents